Phoenix starts liver cancer Phase III

Phoenix Pharmacologics (Lexington, Ky.) started an Italian open-label Phase III trial of its recombinant pegylated arginine deiminase (ADI-PEG 20) targeted enzyme therapy in 80 patients with terminal ...